Medipal Holdings Corporation Reports Consolidated and Unconsolidated Earnings Results for the Fiscal Year Ended March 31, 2017; Provides Earnings Guidance for the Interim Period and Full Year of Fiscal Year Ending March 31, 2018
May 14, 2017
Share
MediPal Holdings Corporation reported consolidated and unconsolidated earnings results for the fiscal year ended March 31, 2017. For the year, the company reported consolidated net sales of ¥3,063,900 million against ¥3,028,187 million a year ago. Operating income was ¥39,650 million against ¥42,283 million a year ago. Ordinary income was ¥53,360 million against ¥55,140 million a year ago. Net income attributable to owners of the parent was ¥29,011 million against ¥30,771 million a year ago. Earnings per share were ¥128.12 against ¥135.89 a year ago. Return on equity was 6.8% compared to 7.6% a year ago. Net cash provided by operating activities was ¥47,954 million compared to ¥21,985 million a year ago. Income before income taxes and minority interests were ¥52,453 million against ¥54,806 million a year ago. Payments for purchase of property and equipment were ¥32,331 million compared to ¥34,392 million a year ago. Payments for purchase of intangible assets were ¥3,506 million compared to ¥4,003 million a year ago. Net assets per share were ¥1,950.25 against ¥1,832.45 a year ago.
For the year, the company reported unconsolidated net sales of ¥16,402 million against ¥13,782 million a year ago. Operating income was ¥11,601 million against ¥10,116 million a year ago. Ordinary income was ¥13,350 million against ¥11,759 million a year ago. Net income was ¥12,824 million against ¥12,138 million a year ago. Earnings per share were ¥56.64 against ¥53.61 a year ago. Net assets per share were ¥1,156.40 against ¥1,118.95 a year ago. Income before income taxes was ¥13,352 million against ¥12,947 a year ago.
The company provides earnings guidance for the interim period and full year of fiscal year ending March 31, 2018. For the interim period, the company expects net sales of ¥1,552,000 million, operating income of ¥17,900 million, ordinary income of ¥24,000 million, and net income attributable to owners of the parent of ¥12,100 million or ¥53.44 per share
For the year, the company expects net sales of ¥3,116,000 million, operating income of ¥42,500 million, ordinary income of ¥56,000 million, and net income attributable to owners of the parent of ¥30,000 million or ¥132.49 per share.
MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The Cosmetics, Daily Product and General Medicine Wholesale segment is engaged in the wholesale of cosmetics, daily miscellaneous goods and general pharmaceuticals. The Veterinary Medicine and Food Processing Raw Materials Wholesale segment is engaged in the wholesale of veterinary products, food additives and food raw materials. The Company is also involved in the provision of cleaning services, the management and operation of logistics centers, the provision of manpower dispatching services and others.
Medipal Holdings Corporation Reports Consolidated and Unconsolidated Earnings Results for the Fiscal Year Ended March 31, 2017; Provides Earnings Guidance for the Interim Period and Full Year of Fiscal Year Ending March 31, 2018
MEDIPAL HOLDINGS CORPORATION 
